EDIT
Price
$5.49
Change
-$0.06 (-1.08%)
Updated
Apr 19, 6:59 PM EST
11 days until earnings call
NVAX
Price
$3.97
Change
+$0.08 (+2.06%)
Updated
Apr 19, 6:59 PM EST
17 days until earnings call
Ad is loading...

EDIT vs NVAX ᐉ Comparison: Which is Better to Invest?

Header iconEDIT vs NVAX Comparison
Open Charts EDIT vs NVAXBanner chart's image
Editas Medicine
Price$5.49
Change-$0.06 (-1.08%)
Volume$1.43M
CapitalizationN/A
Novavax
Price$3.97
Change+$0.08 (+2.06%)
Volume$1.86M
CapitalizationN/A
View a ticker or compare two or three
EDIT vs NVAX Comparison Chart

Loading...

EDITDaily Signal changed days agoGain/Loss if shorted
 
Show more...
NVAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
EDIT vs. NVAX commentary
Apr 20, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and NVAX is a Hold.

COMPARISON
Comparison
Apr 20, 2024
Stock price -- (EDIT: $5.55 vs. NVAX: $3.89)
Brand notoriety: EDIT: Not notable vs. NVAX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 85% vs. NVAX: 38%
Market capitalization -- EDIT: $452.29M vs. NVAX: $545.12M
EDIT [@Biotechnology] is valued at $452.29M. NVAX’s [@Biotechnology] market capitalization is $545.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $550.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.51B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 1 FA rating(s) are green whileNVAX’s FA Score has 0 green FA rating(s).

  • EDIT’s FA Score: 1 green, 4 red.
  • NVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, EDIT is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 3 TA indicator(s) are bullish while NVAX’s TA Score has 2 bullish TA indicator(s).

  • EDIT’s TA Score: 3 bullish, 4 bearish.
  • NVAX’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than NVAX.

Price Growth

EDIT (@Biotechnology) experienced а -15.65% price change this week, while NVAX (@Biotechnology) price change was -9.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.81%. For the same industry, the average monthly price growth was -5.21%, and the average quarterly price growth was +1226.26%.

Reported Earning Dates

EDIT is expected to report earnings on Jul 31, 2024.

NVAX is expected to report earnings on Aug 06, 2024.

Industries' Descriptions

@Biotechnology (-6.81% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for EDIT with price predictions.
OPEN
A.I.dvisor published
a Summary for NVAX with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
NVAX($556M) has a higher market cap than EDIT($452M). NVAX YTD gains are higher at: -18.958 vs. EDIT (-45.212).
EDITNVAXEDIT / NVAX
Capitalization452M556M81%
EBITDAN/AN/A-
Gain YTD-45.212-18.958238%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
EDIT vs NVAX: Fundamental Ratings
EDIT
NVAX
OUTLOOK RATING
1..100
5150
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
87
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
8888
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (24) in the Biotechnology industry is somewhat better than the same rating for NVAX (87). This means that EDIT’s stock grew somewhat faster than NVAX’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NVAX (100). This means that EDIT’s stock grew similarly to NVAX’s over the last 12 months.

EDIT's SMR Rating (97) in the Biotechnology industry is in the same range as NVAX (100). This means that EDIT’s stock grew similarly to NVAX’s over the last 12 months.

EDIT's Price Growth Rating (88) in the Biotechnology industry is in the same range as NVAX (88). This means that EDIT’s stock grew similarly to NVAX’s over the last 12 months.

EDIT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NVAX (100). This means that EDIT’s stock grew similarly to NVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITNVAX
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
N/A
Bearish Trend 5 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend about 1 month ago
77%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Ad is loading...
EDITDaily Signal changed days agoGain/Loss if shorted
 
Show more...
NVAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MYINX7.310.02
+0.27%
MainStay WMC Intl Research Eq Inv
FAAIX26.20-0.05
-0.19%
Fidelity Advisor Asset Manager 70% I
LSHAX19.85-0.04
-0.20%
Kinetics Spin-Off and Corp Rest Adv A
YCGEX29.67-0.07
-0.24%
YCG Enhanced
ETCHX30.19-0.41
-1.34%
Eventide Healthcare & Life Sciences C

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been closely correlated with NTLA. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-1.07%
NTLA - EDIT
68%
Closely correlated
-0.84%
BEAM - EDIT
63%
Loosely correlated
N/A
CRSP - EDIT
61%
Loosely correlated
+1.08%
AXON - EDIT
52%
Loosely correlated
-0.74%
VCYT - EDIT
49%
Loosely correlated
+1.80%
More

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with THRD. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then THRD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
N/A
THRD - NVAX
42%
Loosely correlated
+1.33%
XNCR - NVAX
38%
Loosely correlated
-0.63%
SYRE - NVAX
38%
Loosely correlated
+3.70%
DNLI - NVAX
36%
Loosely correlated
-1.31%
MRNA - NVAX
35%
Loosely correlated
-1.39%
More